Cargando…

Consistent improvement with eculizumab across muscle groups in myasthenia gravis

OBJECTIVE: To assess whether eculizumab, a terminal complement inhibitor, improves patient‐ and physician‐reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti‐acetylcho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mantegazza, Renato, O'Brien, Fanny L., Yountz, Marcus, Howard, James F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448154/ https://www.ncbi.nlm.nih.gov/pubmed/32700461 http://dx.doi.org/10.1002/acn3.51121

Ejemplares similares

Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses
por: Howard, James F., et al.
Publicado: (2021)

Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study
por: Nowak, Richard J., et al.
Publicado: (2020)

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
por: Muppidi, Srikanth, et al.
Publicado: (2019)

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension
por: Mantegazza, Renato, et al.
Publicado: (2021)

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab
por: Vissing, John, et al.
Publicado: (2020)

Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
por: Xiao, Hai, et al.
Publicado: (2021)

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
por: Monteleone, Jonathan P. R., et al.
Publicado: (2021)

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study
por: Jacob, Saiju, et al.
Publicado: (2020)

Complement Inhibition for the Treatment of Myasthenia Gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
por: Vélez-Santamaría, Valentina, et al.
Publicado: (2020)

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis
por: Oyama, Munenori, et al.
Publicado: (2020)

A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
por: Langley, Paul C.
Publicado: (2021)

Current and emerging therapies for the treatment of myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2011)

Animal models of myasthenia gravis: utility and limitations
por: Mantegazza, Renato, et al.
Publicado: (2016)

From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research
por: Mantegazza, Renato, et al.
Publicado: (2020)

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis
por: Vu, Tuan, et al.
Publicado: (2023)

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
por: Mantegazza, Renato, et al.
Publicado: (2018)

Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis
por: Antozzi, Carlo, et al.
Publicado: (2023)

Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
por: Mimori, Masahiro, et al.
Publicado: (2022)

Refractory generalized myasthenia gravis with myasthenic incomplete ophthalmoplegia successfully treated with eculizumab
por: Weidmayer, Sara L., et al.
Publicado: (2023)

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
por: Vu, Tuan, et al.
Publicado: (2023)

Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report
por: Vu, Tuan, et al.
Publicado: (2021)

Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis
por: Katyal, Nakul, et al.
Publicado: (2021)

Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case Series
por: Kang, Seung Ah, et al.
Publicado: (2022)

Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization
por: Iacomino, Nicola, et al.
Publicado: (2023)

Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series
por: Datta, Sorabh, et al.
Publicado: (2020)

Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
por: Murai, Hiroyuki, et al.
Publicado: (2021)

Iatrogenic Kaposi’s sarcoma in myasthenia gravis: learnings from two case reports
por: Frangiamore, Rita, et al.
Publicado: (2021)

Muscle-Specific Kinase Myasthenia Gravis
por: Borges, Lucia S., et al.
Publicado: (2020)

Extraocular Muscle Atrophy in Myasthenia Gravis
por: Pedapati, Radhakrishna, et al.
Publicado: (2022)

Eculizumab improved weakness and taste disorder in thymoma-associated generalized myasthenia gravis with anti-striational antibodies: A case report
por: Amano, Eiichiro, et al.
Publicado: (2019)

Corrigendum to “Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance”
Publicado: (2021)

A mild course of COVID-19 infection in a generalized Myasthenia gravis patient under eculizumab treatment
por: Alis, Ceren, et al.
Publicado: (2022)

Complement Inhibitor Therapy for Myasthenia Gravis
por: Albazli, Khaled, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j4us98dpm74dvi9rmfd19b4mdc